InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.20
(
-0.23%
)
Bitcoin
63,654.48
(
-0.92%
)
Post# of 8162
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Long_shortguy

Send PM Follow Ignore
Followers 2
Posts 220
Boards Moderated 0
Alias Born 10/03/2019

Long_shortguy

Re: None

Monday, 11/02/2020 9:29:42 AM

Monday, November 02, 2020 9:29:42 AM

Post# of 8162
$MMEDF Phase1 Data to Support MindMed's Project Lucy in Preparing Phase 2b Trial for Anxiety Disorders

NEW YORK, Nov. 2, 2020 /CNW/ -- MindMed (NEO: MMED, OTCQB: MMEDF), the leading psychedelic medicine biotech company in partnership with University Hospital Basel's Liechti Lab announces the completion and publication of a Phase 1 study on the acute dose dependent effects of LSD. The completed Phase 1 study will help MindMed in dose-finding and the planning of future Phase 2 clinical trials of LSD in patients with anxiety disorders and other medical conditions.

more at

https://finance.yahoo.com/news/sir-royalty-income-fund-reports-222300913.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up